Healthcare providers who use cloud computing feel safe with the practice, giving cloud computing a satisfaction score of 4.5 out of 5, according to KLAS.
Healthcare providers who use cloud computing feel safe with the practice, giving cloud computing a satisfaction score of 4.5 out of 5, according to a recent KLAS report.
But those holding out on the cloud are doing mainly because of the many remaining questions about the future of cloud computing in healthcare, according to the report “Cloud Computing Perception 2013: The Hybrid Cloud in Healthcare.”
Of the non-users, 66 percent said security was their main concern. They also listed uptime/reliability as a concern (38 percent), as well as loss of control (17 percent), cost (9 percent), and integration (2 percent), according to the report.
“The contrast in this report between cloud users and non-users is really telling,” Erik Westerlind, research director and report author, said in a release. “It really helps providers and vendors get a sense of the gaps that exist within current cloud offerings. Furthermore, providers will understand which vendors might be able to resolve their concerns.”
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.